利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.029 秒)

    Methods of treating leukemia
    1.
    发明授权
    Methods of treating leukemia 有权
    白血病治疗方法

    公开(公告)号：US06747036B2

    公开(公告)日：2004-06-08

    申请号：US10046289

    申请日：2002-01-16

    申请人： Henriette Gourdeau ,  Francis J. Giles

    发明人： Henriette Gourdeau ,  Francis J. Giles

    IPC分类号： A61K31505

    CPC分类号： A61K31/675 ,  A61K31/506 ,  A61K31/70 ,  A61K31/704 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/212 ,  A61K38/32 ,  A61K39/39541 ,  A61K45/06 ,  A61K2035/124 ,  C12N5/0644 ,  C12N2501/03 ,  C12N2501/145 ,  A61K31/505 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/20

    摘要： The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkynyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.

    摘要翻译： 本发明提供了一种用于治疗白血病，更特别是急性骨髓性白血病（AML）的宿主的新方法，其包括向宿主施用治疗有效量的具有式I的化合物：其中B为胞嘧啶或5-氟胞嘧啶，R为 选自包括H，单磷酸酯，二磷酸酯，三磷酸酯，被C 1-6烷基取代的羰基，C 2-6烯基，C 2-6炔基，C 6-10芳基，并且其中每个R c独立地选自H，C 1 C6烷基，C2-6炔基，C2-6炔基和羟基保护基; 并且其中所述化合物基本上为（ - ）对映异构体的形式。

    Methods of treating leukemia
    2.
    发明授权
    Methods of treating leukemia 有权
    白血病治疗方法

    公开(公告)号：US06630480B1

    公开(公告)日：2003-10-07

    申请号：US09536459

    申请日：2000-03-28

    申请人： Henriette Gourdeau ,  Francis J. Giles

    发明人： Henriette Gourdeau ,  Francis J. Giles

    IPC分类号： A61K31505

    CPC分类号： A61K31/675 ,  A61K31/506 ,  A61K31/70 ,  A61K31/704 ,  A61K38/13 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/2013 ,  A61K38/202 ,  A61K38/212 ,  A61K38/32 ,  A61K39/39541 ,  A61K45/06 ,  A61K2035/124 ,  C12N5/0644 ,  C12N2501/03 ,  C12N2501/145 ,  A61K31/505 ,  A61K38/19 ,  A61K2300/00 ,  A61K38/20

    摘要： The present invention provides a novel method for treating leukemia and more particularly acute myelogenous leukemia (AML) in a host comprising administering to the host a therapeutically effective amount of a compound having the formula I: wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and an hydroxy protecting group; and wherein said compound is substantially in the form of the (−) enantiomer.

    摘要翻译： 本发明提供了一种用于治疗白血病，更特别是急性骨髓性白血病（AML）的宿主的新方法，其包括向宿主施用治疗有效量的具有式I的化合物：其中B为胞嘧啶或5-氟胞嘧啶，R为 选自包括H，单磷酸酯，二磷酸酯，三磷酸酯，被C 1-6烷基取代的羰基，C 2-6烯基，C 2-6炔基，C 6-10芳基，并且其中每个R c独立地选自H，C 1 C6烷基，C2-6烯基，C2-6炔基和羟基保护基; 并且其中所述化合物基本上为（ - ）对映异构体的形式。

    Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies
    4.
    发明申请
    Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction Of Response To Therapy And Clinical Behavior, Stratification Of Therapy, And Monitoring Disease In Hematologic Malignancies 有权
    使用血浆蛋白质组学模式进行诊断，分类，治疗反应预测和临床行为，治疗分层和监测血液恶性肿瘤疾病

    公开(公告)号：US20120145891A1

    公开(公告)日：2012-06-14

    申请号：US13325986

    申请日：2011-12-14

    申请人： Maher Albitar ,  Elihu H. Estey ,  Hagop M. Kantarjian ,  Francis J. Giles ,  Michael J. Keating

    发明人： Maher Albitar ,  Elihu H. Estey ,  Hagop M. Kantarjian ,  Francis J. Giles ,  Michael J. Keating

    IPC分类号： H01J49/26

    CPC分类号： G01N33/6851 ,  G01N33/57426 ,  G01N33/6803 ,  G01N33/6848 ,  G01N2800/52 ,  Y10T436/24 ,  Y10T436/25 ,  Y10T436/25625

    摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.

    摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。

    Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction of Response to Therapy and Clinical Behavior, Stratification of Therapy, and Monitoring Disease in Hematologic Malignancies
    8.
    发明申请
    Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction of Response to Therapy and Clinical Behavior, Stratification of Therapy, and Monitoring Disease in Hematologic Malignancies 有权
    使用血浆蛋白质组学模式进行诊断，分类，预防治疗和临床行为，治疗分层和监测血液恶性肿瘤疾病

    公开(公告)号：US20100063747A1

    公开(公告)日：2010-03-11

    申请号：US12582998

    申请日：2009-10-21

    申请人： Maher Albitar ,  Elihu H. Estey ,  Hagop M. Kantarjian ,  Francis J. Giles ,  Michael J. Keating

    发明人： Maher Albitar ,  Elihu H. Estey ,  Hagop M. Kantarjian ,  Francis J. Giles ,  Michael J. Keating

    IPC分类号： G06F19/00

    CPC分类号： G01N33/6851 ,  G01N33/57426 ,  G01N33/6803 ,  G01N33/6848 ,  G01N2800/52 ,  Y10T436/24 ,  Y10T436/25 ,  Y10T436/25625

    摘要： The present invention demonstrates that the diagnosis and prediction of clinical behavior in patients with hematologic malignancies, such as leukemia, can be accomplished by analysis of proteins present in a plasma sample. Thus, in particular embodiments the present invention uses plasma to create a diagnostic or prognostic protein profile of a hematologic malignancy comprising collecting plasma samples from a population of patients with hematologic malignancies; generating protein spectra from the plasma samples with or without fractionation; comparing the protein spectra with clinical data; and identifying protein markers in the plasma samples that correlate with the clinical data. Protein markers identified by this approach can then be used to create a protein profile that can be used to diagnose the hematologic malignancy or determine the prognosis of the hematologic malignancy. Potentially these specific proteins can be identified and targeted in the therapy of these malignancies.

    摘要翻译： 本发明表明，可以通过分析存在于血浆样品中的蛋白质来完成血液恶性肿瘤患者（例如白血病）的临床行为的诊断和预测。 因此，在具体实施方案中，本发明使用血浆来产生血液恶性肿瘤的诊断或预后蛋白质谱，包括从具有血液恶性肿瘤的患者群体收集血浆样品; 产生具有或不具有分级分离的血浆样品的蛋白质光谱; 将蛋白质谱与临床资料进行比较; 并鉴定与临床数据相关的血浆样品中的蛋白质标记。 然后可以使用通过该方法鉴定的蛋白质标记产生可用于诊断血液恶性肿瘤或确定血液恶性肿瘤的预后的蛋白质谱。 潜在地，这些特异性蛋白质可以在这些恶性肿瘤的治疗中被鉴定和靶向。